NANO Share Price Performance
€34.04
30.37 (827.52%)
16.4% overvalued intrinsic discount
€29.24
Fair Value
Price €34.04
AnalystConsensusTarget €29.24
AnalystLowTarget €21.50
AnalystHighTarget €45.00
Fair Value€29.24
Share Pricen/a
Nanobiotix S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
NANO Community Narratives
AN
Fair Value
·Fair Value €29.24 16.4% overvalued intrinsic discount
Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value €21.5 58.3% overvalued intrinsic discount
Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €45 24.4% undervalued intrinsic discount
Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?Read more
AN
€21.5
58.3% overvalued intrinsic discount
Fair Value
Profit Margin
35.86%
Future PE
1.4kx
Price in 2029
€26.04
Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?Read more
AN
€45
24.4% undervalued intrinsic discount
Fair Value
Profit Margin
72.83%
Future PE
15.74x
Price in 2029
€54.47
Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?Read more
AN
€29.24
16.4% overvalued intrinsic discount
Fair Value
Profit Margin
35.4%
Future PE
89.89x
Price in 2029
€35.28
Trending Discussion
Recently Updated Narratives
AN
Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
Fair Value: €21.5 58.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
Fair Value: €45 24.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
Fair Value: €29.24 16.4% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nanobiotix S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.47
- 100.00%
- -73.52%
- -109.2%
About NANO
- Founded
- 2003
- Employees
- 100
- CEO
- WebsiteView website
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
